Borel G A, Schelling J L, Magnenat P
Z Gastroenterol. 1976 Jan;14(1):24-9.
A double blind study was carried out with 14 pairs of patients suffering from acute virus hepatitis in order to determine the action of (+)-cyanidol-3 (2 g daily, administered orally). Among these few patients no significant differences were observed between the two groups. This also holds true for the liver function test with the exception of total serum bilirubin. In the treated patients hyperbilirubinemia decreased significantly faster than in the untreated group (p smaller than 0.05). The values registered with a daily dosis of 1 g (+)-cyanidol-3 did not differ from those recorded in the groups of untreated patients.
